Peptides for Weight Loss: GLP-1s, Tirzepatide, Retatrutide and What Works

Peptides for weight loss are not one category. The proven options are prescription incretin drugs like semaglutide and tirzepatide. The research pipeline includes triple agonists, amylin analogs, and GLP-1/glucagon compounds that may become important, but are not approved weight-loss medicines yet.

Think of this as the broad map — what counts as a weight-loss peptide, which ones have real human evidence, which ones are still investigational, and where to go next for dosing, side effects, calculators, and product-by-product research.

For a narrower drug-class breakdown, read GLP-1 for weight loss. For a ranked head-to-head of the approved GLP-1 family, see best GLP-1 for weight loss.

Short Answer

The strongest evidence is for approved incretin medications:

• Tirzepatide (Zepbound / Mounjaro) has the highest average weight loss among approved injectable options in pivotal obesity trials.
• Semaglutide (Wegovy / Ozempic) is the best-known GLP-1 benchmark and has large obesity and cardiometabolic outcome datasets.
• Liraglutide (Saxenda / Victoza) is older, daily, and generally produces less weight loss than weekly semaglutide or tirzepatide.
• Retatrutide, cagrilintide, CagriSema, and survodutide are research pipeline names to watch, not approved consumer weight-loss peptides.

If you only remember one rule: approval status comes before hype. A peptide with larger early trial numbers can still be a worse real-world choice if it is not approved, not quality-controlled, or not supervised by a qualified clinician.

What Counts As a Weight-Loss Peptide?

In obesity medicine, most "weight-loss peptides" people search for are peptide or peptide-like hormone drugs that copy or modify gut hormone signals.

Pathway	What it does	Common examples
GLP-1	Increases satiety, slows gastric emptying, improves glucose-dependent insulin signaling.	Semaglutide, liraglutide, exenatide, dulaglutide
GIP + GLP-1	Adds a second incretin pathway; in tirzepatide trials this produced larger average weight loss than older GLP-1-only drugs.	Tirzepatide
GLP-1 + GIP + glucagon	Triple agonist approach intended to reduce appetite while also influencing energy expenditure.	Retatrutide
Amylin	Reinforces fullness and slows gastric emptying through a different satiety pathway.	Cagrilintide, CagriSema research
GLP-1 + glucagon	Combines appetite effects with glucagon-receptor activity; still investigational for obesity.	Survodutide

BPC-157, TB-500, ipamorelin, CJC-1295, and most "healing" or "growth hormone" peptides are not weight-loss peptides in the same evidence sense. They may be marketed around body composition, but they are not the compounds driving modern obesity trial results.

Approved vs Investigational

Start here before comparing percent weight loss.

Compound	Class	Status	Evidence snapshot
Semaglutide	GLP-1 receptor agonist	Approved for chronic weight management as Wegovy	STEP 1 reported about 15% average body-weight reduction at 68 weeks with lifestyle support.
Tirzepatide	GIP / GLP-1 dual agonist	Approved for chronic weight management as Zepbound	SURMOUNT-1 reported up to about 21% average body-weight reduction at 72 weeks.
Liraglutide	GLP-1 receptor agonist	Approved for chronic weight management as Saxenda	SCALE reported clinically meaningful weight loss, but below the weekly newer-generation drugs.
Retatrutide	GLP-1 / GIP / glucagon triple agonist	Investigational	Phase 2 obesity data were strong, but it is not approved and Phase 3 outcomes matter.
Cagrilintide / CagriSema	Amylin analog, often studied with semaglutide	Investigational	Important pipeline area because amylin can stack with GLP-1 satiety signaling.
Survodutide	GLP-1 / glucagon dual agonist	Investigational	Phase 2 data suggest meaningful weight loss; not an approved obesity medicine.

Go deeper in the database: semaglutide, tirzepatide, liraglutide, retatrutide, cagrilintide, survodutide, and the weight-loss peptide category hub.

Comparison Guides

Use these when the search is not "what is best overall?" but a specific head-to-head decision.

Comparison	Best use	Read next
Semaglutide vs tirzepatide	Ingredient-level comparison: GLP-1 agonist vs dual GIP/GLP-1 agonist.	Read comparison
Zepbound vs Wegovy	Brand-level comparison for approved weight-loss injections.	Read comparison
Ozempic vs Wegovy	Same active ingredient, different labels and dosing logic.	Read comparison
Semaglutide vs liraglutide	Newer weekly GLP-1 vs older daily GLP-1.	Read comparison
Tirzepatide vs retatrutide	Approved dual agonist vs investigational triple agonist.	Read comparison

Which Peptides Have the Strongest Evidence?

Best approved evidence: tirzepatide and semaglutide

For most people researching peptides for weight loss, the practical comparison is tirzepatide versus semaglutide.

Tirzepatide generally leads on average weight loss in obesity trials. Semaglutide has the broader public footprint and a large evidence base across obesity, diabetes, cardiovascular risk, and metabolic outcomes. Neither choice should be made from trial averages alone: eligibility, contraindications, insurance coverage, side-effect tolerance, and prescriber judgment matter.

Older approved option: liraglutide

Liraglutide still matters because Saxenda is an approved weight-management drug, but it is a daily injection and usually loses the head-to-head convenience and efficacy comparison against weekly semaglutide or tirzepatide.

Strong pipeline signal: retatrutide

Retatrutide is the name most often used in "next-gen GLP-1" discussions because it activates GLP-1, GIP, and glucagon receptors. The Phase 2 obesity trial was striking, but that does not make retatrutide a consumer product. It remains investigational until regulators approve a label. Read the full retatrutide guide and the retatrutide vs GLP-1 comparison before trusting social-media claims.

Pipeline to watch: amylin and glucagon combinations

Cagrilintide, CagriSema, and survodutide are useful to understand because the next wave of obesity drugs may not be GLP-1-only. Amylin analogs add satiety from a different pathway. GLP-1/glucagon drugs try to combine appetite control with energy-expenditure effects. These are research areas, not a reason to use unapproved products.

What Results Should You Expect?

Trial averages are useful for comparing compounds, but they are not promises. Real-world results depend on adherence, dose escalation, side effects, protein intake, resistance training, sleep, starting BMI, metabolic health, and whether the drug can be continued long term.

Compound	Typical research headline	How to interpret it
Tirzepatide	Up to about 21% average body-weight reduction in SURMOUNT-1	Highest approved benchmark, but GI tolerability and access are still limiting factors.
Semaglutide	About 15% average body-weight reduction in STEP 1	Strong GLP-1 benchmark with large clinical experience.
Liraglutide	Lower average weight loss than weekly semaglutide or tirzepatide	Approved but older, daily, and usually less compelling unless access dictates it.
Retatrutide	Phase 2 reported very large average reductions at higher doses	Promising research, but not approved and not a substitute for supervised care.

For a practical timeline, see GLP-1 weight loss before and after. For price and access, see GLP-1 cost, cheapest GLP-1 for weight loss, and where to get GLP-1 online.

Safety Comes Before Optimization

The most common side effects across GLP-1 and incretin-based obesity medicines are gastrointestinal: nausea, vomiting, diarrhea, constipation, reflux, and reduced appetite that can go too far. Labels also warn about more serious risks that need clinician screening, including gallbladder problems, pancreatitis signals, kidney injury in the setting of severe dehydration, hypoglycemia when combined with insulin or sulfonylureas, and boxed warnings related to thyroid C-cell tumors in rodents.

This is why "research peptide" sourcing is a different risk category from a prescribed, regulated medicine. A vial marketed online is not equivalent to an FDA-approved drug product, even when the name sounds familiar.

Read GLP-1 side effects before comparing compounds. For injection-site, alcohol-wipe, vial, and sharps technique, use how to inject peptides safely. The GLP-1 dosage guide is only context for how approved labels structure titration. It is not a dosing instruction.

Calculators and Practical Tools

If you are researching peptide math, use tools that separate calculation from medical advice:

• Reconstitution calculator for concentration math.
• Peptide reconstitution guide for vial mixing, labeling and storage workflow.
• Bacteriostatic water guide for diluent basics and benzyl alcohol warnings.
• Accumulation calculator for repeated-dose half-life visualization.
• Peptide half-life explained for peak, trough, accumulation and steady-state context.
• Peptide storage guide for refrigeration, travel, light and discard rules.
• Unit converter for mg, mcg, and IU conversions.

Calculator shortcuts can help you understand the arithmetic, but they do not validate a source, diagnose eligibility, or replace a prescription plan.

FAQ

What is the best peptide for weight loss?

Among approved medicines, tirzepatide has the strongest average weight-loss trial results, while semaglutide remains the best-known GLP-1 benchmark. The best choice for an individual depends on clinical eligibility, risk factors, coverage, side effects, and medical supervision.

Are peptides for weight loss FDA approved?

Some are. Semaglutide as Wegovy, tirzepatide as Zepbound, and liraglutide as Saxenda have FDA-approved chronic weight-management labels. Many other peptides discussed online are investigational or research-only.

Is retatrutide approved for weight loss?

No. Retatrutide has human clinical trial evidence, but it remains investigational. Treat it as pipeline research until there is an approved label.

Are BPC-157 or TB-500 weight-loss peptides?

No. They are usually discussed as recovery or healing peptides, and they do not belong in the same evidence category as GLP-1, GIP, glucagon, or amylin obesity drugs.

Do GLP-1 peptides work after stopping?

The appetite effect fades after stopping, and weight regain is common. STEP extension data showed meaningful regain after semaglutide withdrawal, which is why these drugs are usually framed as long-term chronic-condition treatments.

Which guide should I read next?

Start with best GLP-1 for weight loss if you want the approved-drug comparison. Read retatrutide if you are researching the next generation. Use the weight-loss peptide database when you want a structured comparison of status, mechanism, half-life, and evidence.

References

1. FDA. FDA approval bulletin for Wegovy (semaglutide) in chronic weight management.

2. FDA. FDA approval announcement for Zepbound (tirzepatide) in chronic weight management.

3. Novo Nordisk. Wegovy prescribing information.

4. Eli Lilly. Zepbound prescribing information.

5. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine.

6. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine.

7. Pi-Sunyer X, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine.

8. Jastreboff AM, et al. Retatrutide for obesity: a phase 2 trial. New England Journal of Medicine.

9. Rubino D, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide.

10. FDA. FDA concerns with unapproved GLP-1 drugs used for weight loss.